CircuLex Human RBP4 ELISA Kit

MBL
Product Code: MBL-CY-8072
Product Group: ELISA Kits
Supplier: MBL
CodeSizePrice
MBL-CY-807296 Assays£577.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Human
Regulatory Status: RUO
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
4°C
Storage:
4°C

Images

1 / 1

Documents

Further Information

Background:
Members of the lipocalin family, RBP4, FABP4 and NGAL (Lipocalin 2), which are produced from adipocytes, have recently been reported to play important roles in regulating systemic energy homeostasis, insulin sensitivity, and inflammation in animal models (1-5). Transgenic overexpression of RBP4 or injection of recombinant RBP4 in normal mice causes insulin resistance (1). Conversely, genetic deletion of RBP4 enhances insulin sensitivity. Graham et al. (2006) found that serum RBP4 levels correlated with the magnitude of insulin resistance in human subjects with obesity, impaired glucose tolerance, or type 2 diabetes and in non-obese, non-diabetic subjects with a strong family history of type 2 diabetes (6). Elevated serum RBP4 was associated with components of the metabolic syndrome, including increased body mass index (BMI), waist-to-hip ratio, serum triglyceride levels, and systolic blood pressure and decreased high-density lipoprotein cholesterol levels (6-8). Adipocyte GLUT4 protein and serum RBP4 levels were inversely correlated. Graham et al. concluded that RBP4 is elevated in serum before the development of frank diabetes and appears to identify insulin resistance and associated cardiovascular risk factors in subjects with varied clinical presentations.
Description:
The CycLex Research Product CircuLex Human RBP4 ELISA kit is used for the quantitative measurement of Human Retinol Binding Protein 4 (RBP4) in serum, plasma and other biological media.
Gene IDs:
Human: 5950 Mouse: 19662
Kit Components:
Microplate, Wash Buffer, Dilution Buffer, Human RBP4 Standard, HRP conjugated Detection Antibody, Substrate Reagent, Stop Solution
Measurement Range:
Dilution factors need to be taken into consideration in calculating the Human RBP4 concentration. Results exceeding diluted Human RBP4 level of 100 ng/ml should be repeated with diluted samples.
Sensitivity:
better than 1.08 ng/mL of sample.
Target:
RBP4

References

1. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. : Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. : Nature 436: 356?62, 2005 2. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, et al. : Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 1: 107?119, 2005 3. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. : Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274: 1377?9, 1996 4. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A. : Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 53: 34-41, 2007 5. van Dam RM, Hu FB. : Lipocalins and insulin resistance: etiological role of retinol-binding protein 4 and lipocalin-2? Clin. Chem. 53: 5-7, 2007 6. Graham, T. E.; Yang, Q.; Bluher, M.; Hammarstedt, A.; Ciaraldi, T. P.; Henry, R. R.; Wason, C. J.; Oberbach, A.; Jansson, P.-A.; Smith, U.; Kahn, B. B.: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New Eng. J. Med. 354: 2552-2563, 2006. 7. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS.: Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 29: 2457-61, 2006 8. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, Ludvik B. Serum retinol-binding protein-4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2006 Dec 12; [Epub ahead of print]